Well, the real differentiator (and not a matter of opinion) is...

Well, the real differentiator (and not a matter of opinion) is that Nexavar is a convenient pill, whereas PI-88 needs to be administered via painful injection. Nexavar is also approved for liver and kidney cancer, and has already got an extensive safety profile.

It is good that they finally acknowledge that Bayer/Onyx are going to move into the post-resection market. Make no mistake - it is going to happen. And their Phase III trial will no doubt only take weeks, not years (just like their last Phase III was closed early due to stellar results).

It's time to cut the crap, and recognise Nexavar for the blockbuster it is. PI-88 is dead. Any valuation that exceeds cash is totally nonsensical, so take profits while you can.